SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Elder Pharmaceuticals surges on plan to expand its footprint in dermatology segment

08 Sep 2014 Evaluate

Elder Pharmaceuticals is currently trading at Rs. 191.00, up by 4.50 points or 2.41% from its previous closing of Rs. 186.50 on the BSE.

The scrip opened at Rs. 188.30 and has touched a high and low of Rs. 192.85 and Rs. 188.00 respectively. So far 6123 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 377.40 on 06-Sep-2013 and a 52 week low of Rs. 162.00 on 14-Aug-2014.

Last one week high and low of the scrip stood at Rs. 196.25 and Rs. 184.00 respectively. The current market cap of the company is Rs. 394.31 crore.

The promoters holding in the company stood at 25.26% while Institutions and Non-Institutions held 29.77% and 44.97% respectively.

Elder Pharmaceuticals is planning to expand its footprint in the Rs 4,000-crore dermatology segment in a big way. The company already has some presence in skin care category but with a slew of new launches, it plans to grab a market share of 4-5 per cent in each sub-category.

Meanwhile, the company has introduced ‘Eslite Plus’, a hydroquinone and combination cream for skin lightening; ‘Ultraguard’, a sunscreen containing American & European FDA standard ingredients; ‘B-New’, an anti-aging cream; ‘Camoflage’, a stretch-marks & pregnancy line remover and ‘Skin O2’, a multi vitamin product in soft gelatin capsules for skin nourishment.

Elder Pharmaceuticals has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

 

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×